Loading news...
TOKYO--(BUSINESS WIRE)-- #cancer--Japan approves Alpha DaRT for head & neck cancer, becoming the first market outside Israel.
- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that Japan's Ministry of Health, Labour and Welfare (“MHLW”) has granted regulatory (Shonin) marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally recurrent head and neck cancer.
Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) and Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation. Insider and Institutional Ownership 2.7% of
Alpha Tau Medical Ltd. (NASDAQ: DRTS - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totaling 527,362 shares, a growth of 111.0% from the December 31st total of 249,905 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain -
DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.
Alpha Tau Medical is positioned for major catalysts in 2026, with its differentiated, tumor-agnostic Alpha DaRT technology gaining visibility and momentum. Pancreatic cancer and GBM readouts expected in 2H26 have the potential to be inflection points. At ~$550M market cap, a strong cash position, and multiple upcoming readouts, DRTS offers attractive upside as it approaches proof-of-concept in high-impact oncology indications.
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect - - Alpha DaRT currently being studied together with first-line chemotherapy in U.S. multi-center pilot trial for newly diagnosed pancreatic cancer - JERUSALEM, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC).
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted - - Module submitted in parallel to execution of ReSTART pivotal study ( Re current S CC T reatment with A lpha DaRT R adiation T herapy), which is expected to complete recruiting patients in Q1 2026 - JERUSALEM, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced the submission of the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA), following the FDA's previous decision to allow the Company to use the more flexible modular approach.
Alpha Tau Medical surged in after-hours trading after treating the first patient in its pilot study for recurrent glioblastoma with Alpha DaRT therapy.
- First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of Alpha Tau's broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - JERUSALEM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology.
- Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study -
Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) is projected to release its Q3 2025 results before the market opens on Tuesday, November 18th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Individuals can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call
JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.
- Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation -
Alpha DaRT, a unique localized alpha radiation therapy, has shown potential best-in-class efficacy and safety across multiple solid tumors. Currently enrolling patients in cSCC, HNSCC, pancreatic, and GBM (before year end), with a number of milestones across each indication over the next 12-18 months. Despite promising early data and broad potential, Alpha Tau's is currently significantly undervalued at ~$330 million market cap, especially in light of recent acquisitions and trading activity.
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program –
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -